Sofinnova Partners closed its Capital XI flagship fund at €650 million (about $750 million), exceeding its initial target and earmarked for early‑stage biopharma and medtech investments. The firm said the fund will back therapeutics and device startups and provide extended follow‑on capacity to support companies through multiple financing rounds. Sofinnova emphasized hands‑on operational support and noted early deployments across Europe and North America. The close signals renewed VC appetite for science‑driven, patent‑backed ventures and adds notable dry powder for seed and Series A deals in a cautious fundraising climate.